Trial Information

Summary: A Phase II, Randomized, Open-Label, Comparative Study of Epoetin Alfa (Procrit) 80,000 Units or 120,000 Units Every Three Weeks Versus Darbepoetin (Aranesp) 500 mcg Every Three Weeks in Anemic Cancer Subjects Receiving Chemotherapy

The study will compare the control of anemia ( no need or less need for blood transfusions) of the two named products

Patient Inclusion Criteria
Must be receiving a minimum of twelve chemotherapy treatments

Patient Exclusion Criteria
No prior treatment with either product within thirty days of consent for the trial

For more information,

Contact:

Kelly Beauchamp, Clinical Research Coordinator
Gainesville Hematology/Oncology Associates
1147 N.W. 64th Terrace
Gainesville, FL 32605
Telephone: 352-264-2543
Fax: 352-331-3802
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:46:22 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA